Verrica Pharmaceuticals announces FDA approval of Ycanth topical solution

Verrica Pharmaceuticals announced FDA approval of Ycanth topical solution for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. Ycanth is for topical use only. Ycanth is not for oral, mucosal, or ophthalmic use. Local skin reactions at the application site were observed in 97% of subjects treated with Ycanth during clinical trials. Local skin reactions included vesiculation, pruritus, pain, discoloration, and erythema. Ycanth is a proprietary drug-device combination product containing a GMP-controlled formulation of cantharidin delivered via a single-use applicator, allowing for precise topical dosing and targeted administration. Verrica plans to make Ycanth available by September.